Vumedi $104 Million Series B Funding Explained: AI Physician Learning, Oak HC/FT and What Doctors Get

on

Vumedi 104 million Series B funding explained — a surgical team at work, the kind of specialist practice Vumedi's AI learns from

Illustrative image: a surgical technologist assisting a surgeon during an orthopaedic procedure. No official Vumedi product visual is available in the public announcement, so this image illustrates the specialist practice the platform is built on. Image: Wikimedia Commons / U.S. Navy, Lt.j.g. Gabriela Santesteban, public domain

TL;DR — Vumedi, the Oakland platform where doctors learn from other doctors' videos, announced expanded AI-powered learning on 10 November 2026, built on a $104 million Series B growth investment from Oak HC/FT. The Vumedi 104 million Series B funding explained in one line: investors are betting that the fastest way for a doctor to keep up with new medicine is to ask an AI trained on how leading specialists actually practise — not just what the textbooks say.

Key Highlights

  • Vumedi announced expanded AI-powered physician learning on 10 November 2026, funded by a $104 million Series B growth investment from Oak HC/FT — roughly ₹936 crore.
  • The AI draws on 100,000+ physician-led videos and nearly 5,000 podcast episodes across 21+ specialties, and answers a clinician's question with how multiple specialists approach the same problem.
  • Since launching less than a year ago, the AI tools have been used by 150,000+ NPI-verified clinicians, generating 1 million+ interactions.
  • Doctors now spend 4.3 million+ minutes a month learning on the platform — 56 million+ minutes in the past 12 months.
  • One figure needs a careful read: funding databases previously recorded this Series B at about $80 million in May 2025, while Vumedi's announcement describes it as $104 million — see the note below.

What happened?

Vumedi, the peer-to-peer learning community for physicians based in Oakland, California, announced on 10 November 2026 that it has expanded its AI-powered learning capabilities. The announcement, carried in a Business Wire release, says the expansion builds on a $104 million Series B growth investment from Oak HC/FT, a venture and growth equity firm specialising in healthcare and technology.

The company was founded in 2008 by Roman Giverts and, unusually for a health-tech startup, grew for roughly sixteen years without a traditional venture round, according to independent profiles. That history makes the size of this round notable: it is the company's first major institutional backing, and it is being spent on talent, research and development, product development and outreach — in other words, on turning a video library into an AI search engine for clinical know-how.

The timing is tied to a real problem in medicine. Research cited by the company found that the time needed for a new treatment to reach peak adoption has stretched from about two to three years to six to seven years. New studies, therapies and devices arrive faster than any individual doctor can read, and Vumedi's pitch is that the gap is best closed by the experience of specialists who have already used the new treatment — not by another literature summary.

What Vumedi's AI actually does

Most medical AI tools retrieve or summarise published papers. Vumedi's does something different: a doctor asks a clinical question, and the AI surfaces the most relevant specialist perspectives from its library — including expert-led content that does not exist in the published literature — and synthesises how multiple experts approach the same problem. The clinician can then jump to the time-stamped moment in the underlying video or podcast episode to see the full context, from procedural technique to treatment sequencing.

The engagement numbers the company published with the announcement suggest doctors are actually using it, not just trying it once:

Vumedi by the numbers Figure (company-reported, Nov 2026)
Series B growth investment $104 million from Oak HC/FT
Physician-led videos in the library 100,000+
Podcast episodes Nearly 5,000
Specialties covered 21+
NPI-verified clinicians using the AI tools 150,000+
AI interactions since launch (under a year) 1 million+
Learning minutes in the past 12 months 56 million+
New videos added in the past 12 months 20,000

"AI is making it dramatically easier for physicians to get information. That makes access to real clinical experience more important," said Roman Giverts, founder and CEO of Vumedi. "Some of the most valuable knowledge in medicine lives in how experienced physicians actually practice, including how they interpret new evidence, sequence treatments, perform procedures and manage the cases that aren't straightforward."

Vumedi 104 million Series B funding explained — surgeons conducting laparoscopic surgery, an example of the specialist procedures in Vumedi's video library

Illustrative image: surgeons conducting laparoscopic surgery in a newly opened operating facility. Image: Wikimedia Commons / U.S. Air Force, Tech. Sgt. Rachel Maxwell, public domain

The $80 million question: read the round carefully

There is one wrinkle worth stating plainly. Funding databases such as PitchBook and CB Insights previously recorded Vumedi's Series B at about $80 million, first closed in May 2025, with roughly $82 million raised in total to that point. Vumedi's November 2026 announcement describes the round as a $104 million Series B growth investment. The company has not published a breakdown, so the most likely explanations are an extension of the round, secondary transactions, or a combination of equity and venture debt — but that is not confirmed, and this post does not present the $104 million as a brand-new, single-tranche raise. What is confirmed is the figure the company itself is now using, the investor, and the AI expansion the money is funding.

It is also worth knowing how the platform makes its money: independent profiles note that pharmaceutical and medical-device companies sponsor evidence-based programming on Vumedi. That is a normal model for clinician education, but it is also why the verification rules matter — every uploader is a verified clinician, and the AI is grounded in that closed library rather than the open web.

Why it matters for India readers

Vumedi is built around US clinician verification — NPI numbers are an American identifier — so its AI tools are not aimed at Indian doctors today. But the problem it solves is exactly the one Indian medicine faces: a huge, fast-growing body of new evidence and a treatment-adoption lag measured in years, not months. Indian medical-education platforms, hospital networks and the doctors preparing for rapidly changing guidelines all face the same question Vumedi is answering — whether peer experience, properly verified and searchable, can move faster than journals alone. If the model works at Vumedi's scale, expect Indian health-tech to copy it; if the sponsorship model ever clouds the content, that will be the test to watch.

For the funding market, the round is another data point in a busy week: AI startups dominated the November funding lists, from Mercor's $750 million Series D to Nominal's $240 million Series C — and Vumedi shows the money is reaching applied AI in healthcare, not just model builders.

Should you care?

✅ Yes, if you follow health-tech or applied AI. Vumedi is a useful counter-example to the idea that medical AI must mean a chatbot summarising papers: grounding answers in verified specialist practice is a defensible, genuinely different approach, and 150,000 clinicians using it in under a year is real traction. ⏳ Watch, don't over-read, the $104 million. Until the company clarifies how that figure relates to the $80 million recorded in May 2025, treat it as the company's stated round size, not a fresh single cheque. And the sponsorship-funded model deserves the same scrutiny any clinician-education platform gets: the content is only as trustworthy as the verification behind it.

FAQs

What is Vumedi?
Vumedi is a peer-to-peer learning community for physicians, founded in 2008 in Oakland, California. Clinicians watch videos and listen to podcasts from leading specialists — more than 100,000 videos across 21+ specialties — to see how experts perform procedures, evaluate new treatments and handle complex cases.

How much did Vumedi raise in its Series B?
Vumedi's November 2026 announcement describes a $104 million Series B growth investment from Oak HC/FT. Funding databases previously recorded the Series B at about $80 million when it first closed in May 2025; the company has not published a breakdown of how the $104 million figure is composed.

What does Vumedi's AI do for doctors?
A doctor asks a clinical question and the AI surfaces the most relevant specialist perspectives from the video and podcast library, synthesises how multiple experts approach the problem, and links to the exact time-stamped moment in the source video or episode. It has been used by more than 150,000 NPI-verified clinicians, generating over 1 million interactions since launching less than a year ago.

Who invested in Vumedi?
Oak HC/FT, a venture and growth equity firm specialising in technology and healthcare. Founded in 2014, it has invested in more than 120 portfolio companies and manages more than $10 billion in assets. Its co-founder and managing partner Andrew Adams said Vumedi is "a leading education destination for providers".

Takeaway

Vumedi's $104 million Series B is a bet that the most valuable medical knowledge is not in papers but in practice — and that an AI trained on verified specialists can deliver it faster than any journal. The traction is real; the round's exact composition deserves the one careful footnote above. If you work in health-tech, the model is worth studying; if you are a clinician, the question to ask any such platform is always the same — who verified the experts, and who paid for the content?

For the wider funding picture this week, read our explainer on Bay's $50 million raise for enterprise AI agent security.

Sources

Comments

Post a Comment